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Strengths and limitations of this study
 ► This is an up- to- date systematic review and meta- 
analysis to determine the nature and extent of 
published literature on the association of vision im-
pairment and blindness with mortality.
 ► This review will comprehensively assess published 
peer- reviewed English- language manuscripts, with 
no time period or geographical restrictions.
 ► This will be the first review to carry out a formal 
assessment of risk of bias in included studies 
and the certainty of the evidence on this topic us-
ing the Grades of Recommendation, Assessment, 
Development and Evaluation approach.
 ► A potential limitation might be the paucity of pub-
lished literature on how specific levels of vision im-
pairment contribute to mortality.
 ► Another potential limitation is that the complexity of 
pathways between eye health and mortality is un-
likely to be fully described and tested in the current 
literature.
AbStrACt
Introduction Due to growth and ageing of the world’s 
population, the number of individuals worldwide with vision 
impairment (VI) and blindness is projected to increase rapidly 
over the coming decades. VI and blindness are an important 
cause of years lived with disability. However, the association 
of VI and blindness with mortality, including the risk of bias in 
published studies and certainty of the evidence, has not been 
adequately studied in an up- to- date systematic review and 
meta- analysis.
Methods and analysis The planned systematic review 
and meta- analysis will adhere to the Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses guidelines. 
Databases, including MEDLINE Ovid, Embase Ovid and Global 
Health, will be searched for relevant studies. Two reviewers 
will then screen studies and review full texts to identify 
studies for inclusion. Data extraction will be performed, 
and for included studies, the risk of bias and certainty 
of the evidence will be assessed using the Grades of 
Recommendation, Assessment, Development and Evaluation 
approach. The prognostic factor in this study is visual 
function, which must have been measured using a standard 
objective ophthalmic clinical or research instrument. We 
will use standard criteria from WHO to categorise VI and 
blindness. All- cause mortality may be assessed by any 
method one or more years after baseline assessment of 
vision. Results from included studies will be meta- analysed 
according to relevant sections of the Meta- analysis Of 
Observational Studies in Epidemiology checklist.
Ethics and dissemination This review will only include 
published data; therefore, ethics approval will not be sought. 
The findings of this review and meta- analysis will be 
published in an open- access, peer- reviewed journal and will 
be included in the ongoing Lancet Global Health Commission 
on Global Eye Health.
IntroduCtIon
More than 250 million people globally are 
blind or visually impaired, and the number 
affected is projected to increase due to growth 
and ageing of the world’s population.1 Poor 
vision is associated with an increased risk of 
dementia, depression, falls and loss of indepen-
dence.1 2 Some prior studies have also reported 
that individuals with vision impairment (VI) 
have an increased risk of mortality compared 
with those with normal vision.3 However, an 
up- to- date systematic review and meta- analysis 
of the published literature, including a formal 
assessment of risk of bias and certainty of the 
evidence, is needed to characterise the rela-
tionship between VI and mortality globally.
In order to guide a systematic review and 
meta- analysis of the association of VI with 
mortality, we developed a theoretical frame-
work adapted from the WHO International 
Classification of Functioning.4 Our framework 
illustrates the possible relationship between VI 
and mortality, as well as the diverse mediating 
and moderating factors that may contribute 
to this association (figure 1). As depicted, 
we hypothesise that VI, operationalised as a 
decline in visual function, is associated with 
mortality through its effects on systemic health 
(eg, an increased risk of chronic disease, frailty 
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Figure 1 Theoretical framework for the association of 
vision impairment and mortality. This figure presents the 
hypothesised relationships between vision impairment 
and mortality that inform the systematic review and meta- 
analysis. *Conditions such as cardiovascular disease, 
diabetes, hypertension and stroke that increase the risk 
of both vision impairment and mortality. Adapted from 
the model of disability in international classification of 
functioning, disability and health:ICF. Geneva:WHO;2001. ICF, 
International Classification of Functioning.
and decreased functional status). Factors such as participa-
tion (social, physical, daily activities) both impact and are 
impacted by visual and systemic health (eg, VI increases 
the risk of social isolation, which in turn affects overall 
health). Finally, individual- level traits, environmental and 
health system characteristics, smoking and conditions with 
both ocular and systemic manifestations (eg, cardiovascular 
disease, diabetes, hypertension, stroke) may simultaneously 
increase the risk of both VI and mortality.
A prior systematic review and meta- analysis published 
in 2016 summarised findings from 29 prospective studies 
that assessed the association between vision and the risk 
of mortality.3 That study reported that the risk of death 
was 36% higher in the group with the highest level of VI 
compared with those without VI, and that for each 0.1 
increment change in logarithm of minimum angle of 
resolution (logMAR) the risk of death increased by 4%. 
However, the study had several limitations. First, it did not 
assess or account for the level of bias in included studies 
or certainty of the evidence. Additionally, three included 
studies assessed VI based on billing codes, and seven used 
self- reported VI rather than objective quantifiable measures. 
Self- reported visual function may reflect a distinct latent 
construct,5 in which case the pooled analysis of studies that 
assessed visual function objectively and subjectively may 
bias results in an unpredictable fashion. The highest level 
of VI was used as a predictor of mortality even though VI 
categories varied from study to study. Search terms also did 
not include specific eye conditions (eg, glaucoma or cata-
ract), so studies of the association between mortality and 
VI due to these conditions may have been omitted. Finally, 
several prospective studies have been published in recent 
years that report the association between VI and mortality 
in geographic regions, such as sub- Saharan Africa, that 
were under- represented in the prior systematic review and 
meta- analysis.
The study described in this protocol will seek to provide 
an updated review of the literature and estimate of the 
effect of VI on the risk of mortality. Notably, the complex 
pathways that may mediate the association between VI 
and mortality may not have been fully described or tested 
in prior studies, though doing so will be an important 
future step toward optimising outcomes for those with VI 
and blindness. By including an assessment of the risk of 
bias to inform an overall judgement of the certainty of the 
evidence, and by considering newly published studies from 
under- represented geographical regions, this systematic 
review and meta- analysis will make an important contribu-
tion to global eye health.
objectives/review questions
This systematic review and meta- analysis will aim to answer 
the following questions:
1. What is the extent, strength and quality of the pub-
lished evidence that VI is associated with the risk of 
all- cause mortality?
2. To what degree does VI affect the risk of all- cause mor-
tality, and does this risk vary based on level of visual 
function?
MEthodS And AnAlySIS
Protocol and registration
This work was undertaken as part of the Lancet Global Health 
Commission on Global Eye Health. We have drawn on 
the PROGnosis RESearch Strategy framework for prog-
nosis research in developing this protocol.6 The protocol 
has been registered prospectively with the Open Science 
Framework (OSF) registry and can be viewed at: http:// 
osf. io/ weu96. Any future amendments to the protocol will 
be noted in the OSF registration. Results of the systematic 
review and meta- analysis described herein will be reported 
according to the relevant section of the Preferred Reporting 
Items for Systematic Reviewa and Meta- Analyses (PRISMA) 
checklist for systematic reviews.7 The completed PRISMA- 
Protocols checklist is presented in online supplementary 
appendix 1.8
Search method for identification of studies
Electronic searches
We will search the following electronic databases:
1. MEDLINE Ovid (1946–2020).
2. Embase Ovid (1980–2019).
3. Global Health (1973–2020).
The full electronic search strategy for MEDLINE Ovid 
is included in online supplementary appendix 2. We will 
not limit the search by date. Articles will be included if 
they were published before 1 February 2020. As noted 
above, the search will be limited to English language 
articles and will not include conference abstracts or grey 
literature.
3Ehrlich JR, et al. BMJ Open 2020;10:e037556. doi:10.1136/bmjopen-2020-037556
Open access
Searching other resources
We will identify additional studies by searching the refer-
ence lists of relevant publications identified through the 
electronic searches and by searching any prior review arti-
cles on this topic.
Criteria for considering studies to review
Types of studies
We will include published prospective and retrospective 
cohort studies with a baseline assessment of the exposure 
(vision) and longitudinal assessment of the outcome (all- 
cause mortality) over a period of at least 1 year. Since age 
is a strong risk factor for mortality and VI, estimates of the 
effect of VI on mortality risk must be age adjusted. Inter-
ventional studies and studies where all participants had a 
specific systemic disease (eg, diabetes) will be excluded 
due to the difficulty of separating the possible effect of VI 
on mortality from the effect of an intervention or systemic 
disease on mortality. Only peer- reviewed articles published 
in English will be included. We will not include grey litera-
ture or conference abstracts. We will consider publications 
from all years and geographical regions.
Types of participants
Men and women aged 40 years and above at the time of 
enrolment will be eligible for inclusion. We are restricting 
the population to this age group of because of the low rate 
of mortality in younger individuals.
Types of prognostic factors
The prognostic factor in this study is visual function. Visual 
function must have been measured using a standard objec-
tive ophthalmic clinical or research instrument, including, 
but not limited to visual acuity, visual fields, contrast sensi-
tivity and stereoacuity. If a study contains data on the effect 
of multiple measures of visual function (eg, visual acuity 
and visual fields), we will report each of these and they will 
be included in the meta- analysis. Studies where visual func-
tion was self- reported or determined based on billing codes 
will not be included.
We will consider several cut- points:
1. For visual acuity, we will consider presenting binocular 
visual acuity or visual acuity in the better- seeing eye (if 
both are reported we will use the binocular measure-
ment). Definitions of VI will be based on the catego-
ries of VI in the WHO International Classification of 
Diseases.9 People with each of the following categories 
of VI will be compared with those with better vision.
a. Mild VI or worse will be defined as visual acuity 
<6/12.
b. Moderate VI or worse will be defined as visual acuity 
<6/18.
c. Severe VI or worse will be defined as visual acuity 
<6/60.
d. Blindness will be defined as visual acuity <3/60.
2. For other measures of vision, we will adopt study- 
specific definitions of VI since standardised definitions 
do not exist or are not widely used.
We will use the definitions of VI and blindness reported 
in the included studies that most closely correspond to 
these definitions. However, we anticipate heterogeneity in 
these measures across studies. For example, studies may 
vary in whether they consider uncorrected, presenting or 
best- corrected visual acuity; they may include measures of 
visual fields, stereoacuity and/or contrast sensitivity in their 
definition; they may consider the worse- seeing eye, better- 
seeing eye or binocular visual acuity; and they may employ 
different categorical definitions of VI and blindness. We 
will be inclusive but will explore this heterogeneity in meta- 
regression analyses (see Meta- regression section). When 
available, we will also use continuous measures of vision (eg, 
logMAR or log contrast sensitivity) in our analyses.
Types of outcome measures
Outcome
1. The outcome is all- cause mortality one or more years 
after baseline assessment of vision. Mortality may be 
reported using different measures of effect size and we 
will include all measures.
Ascertainment of death may be made by any method, 
including but not limited to review of vital records (eg, death 
certificates) or report by an informant. We have chosen to 
include studies that ascertained death by informant report 
since not all countries provide access to complete vital 
records and we seek to include studies from all regions of 
the world. If sufficient data are available, we will consider 
performing analyses to determine the association between 
VI and cause- specific mortality.
Measures of effect
To determine the association between VI and mortality, we 
will extract age- adjusted measures of effect reported in each 
included study. All measures of effect must be age adjusted. 
When available, we will extract measures that have adjusted 
for other theoretical confounders (eg, socioeconomic 
status, smoking status, cardiovascular disease, diabetes, 
hypertension, stroke) as depicted in our conceptual frame-
work (figure). To the extent that it is possible to do so, we 
will choose measures of effect that are not adjusted for 
likely mediators on the pathway between VI and mortality, 
such as overall health or functional status.
data collection and analysis
Selection of studies
Two review authors will independently screen search results 
based on title and abstract and will remove reports that 
clearly do not fall into the scope of this review. Disagree-
ments will be resolved by discussion and consultation with 
another author as needed. We will acquire the full text of 
all publications appearing to potentially meet criteria for 
inclusion in this review. Two review authors will screen all 
of these reports for method of visual function assessment, 
type of study design, duration of follow- up, and ascertain-
ment of death. Any disagreements will be discussed and if 
they cannot be resolved will be arbitrated by a third review 
author. Screening of search results will be conducted using 
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Covidence systematic review software (Veritas Health Inno-
vation, Melbourne, Australia; available at www. covidence. 
org).
Data extraction and management
Data extraction will be guided by the relevant sections of 
the CHecklist for critical Appraisal and data extraction 
for Systematic Reviews of prediction Modelling Studies 
checklist.10 Two review authors will independently extract 
the following data from each included study: study design, 
participant characteristics, study population and size, study 
setting, study dates, follow- up duration, diagnostic and 
ascertainment methods, study attrition, estimates of effect 
size, and standard errors. Disagreements will be resolved by 
discussion and consultation with another author as needed; 
if they cannot be resolved they will be arbitrated by a third 
review author. The types of data likely to be reported as 
estimates of effect size include hazard ratios, risk ratios, 
rate ratios, standardised mortality ratios, cumulative inci-
dence rates, proportions, survival curves and/or ORs. Data 
extraction and management will be conducted using Covi-
dence systematic review software.
Assessment of risk of bias
Two reviewers will independently assess the risk of bias in 
each included study using the Quality in Prognostic Studies 
(QUIPS) tool.11 They will assess study participation, attri-
tion, prognostic factor measurement, outcome measure-
ment, confounding and statistical analysis and reporting. 
Likely confounders include systemic health conditions that 
increase risk of VI and mortality (eg, diabetes), access to 
medical care, socioeconomic status and smoking status. For 
each QUIPS domain, we will assign a rating of low, moderate 
or high risk of bias. Ratings of each of the domains in 
QUIPS will be considered to provide an overall risk of bias 
assessment for each study. Only studies receiving a rating of 
low risk of bias in all of the aforementioned domains will 
be given an overall ‘low’ rating; any study that received one 
or more ratings of high risk of bias will receive an overall 
‘high’ rating; other studies will receive an overall ‘medium’ 
risk of bias rating.
Measures of association
We will extract summary measures of the association 
between VI and risk of mortality. We anticipate that some 
studies will report an overall event rate for the study period, 
while others may provide estimates of effect size. For all esti-
mates, we will extract SEs; if they are not reported we will 
extract 95% CIs and use these to calculate standard errors. 
As noted, we will preference measures that are adjusted for 
theoretical confounders but not mediators of the associa-
tion between VI and mortality. We will extract definitions of 
VI and blindness to permit analyses based on specific levels 
of VI or blindness, insofar as there are sufficient data avail-
able to do so.
Dealing with missing data
We will include studies that follow individuals with and 
without VI (or with varying levels of VI) for 1 or more 
years and report the proportion who died, even if there 
are missing data. If all of the necessary information are not 
found in a published study, for articles published in 2010 
or later we will email the corresponding author to solicit 
further information. If we are unable to obtain the neces-
sary information, we will document in the review that we 
attempted to contact the study authors. We will consider 
the sensitivity of our meta- analysis to the effect of missing 
data. We will analyse the data that is available rather than 
imputing missing data. We will document and discuss the 
possible effect of missing data on each study and on the 
overall review and meta- analysis.
Assessment of heterogeneity
Clinical heterogeneity will be assessed by comparing key 
participant characteristics at the study level (eg, age, sex, 
ocular diagnoses). Methodological heterogeneity will also 
be considered, including a comparison of the risk of bias 
of included studies. We will assess statistical heterogeneity 
by inspecting forest plots and through inspection of the 
I2 and τ2 statistics to examine the proportion of hetero-
geneity across studies that is due to chance. If high levels 
of heterogeneity are detected (I2 >50%), we will explore 
likely sources of this heterogeneity (see the Meta- regression 
section). We will also assess small study effects, one of which 
may be publication bias, by preparing a funnel plot,12 which 
is a scatter plot of effect size versus precision (SE).
data synthesis
Data synthesis and meta-analysis approaches
Methods and results of our meta- analysis will be guided 
by relevant sections of the Meta- analysis Of Observational 
Studies in Epidemiology checklist.13 Meta- analyses will be 
performed using a random- effects, generic inverse variance 
meta- analysis model in Stata V.16 (StataCorp). Random- 
effects, rather than fixed effects, models will be used since 
it is likely that the true effect of VI on mortality varies from 
study to study due to differences in study populations and 
contexts. The meta- analysis will be summarised using the 
pooled estimate, its 95% CI, and between study variance 
(τ2). The meta- analysis will be performed and results will 
be reported for adjusted effect estimates. We will conduct 
meta- analyses separately for the different types of effect 
measures (eg, HRs, ORs and risk ratios). The log of each 
study estimate and its confidence intervals will be used to 
determine the study SE; these will be then pooled using 
random- effects meta- analysis before taking the exponent 
of the results to present the pooled effect estimate on the 
original scale. We will assess and report the overall quality of 
evidence from our meta- analysis using the modified Grades 
of Recommendation, Assessment, Development and Evalu-
ation tool.14
Meta-regression
Where data permit, we will investigate the relationship 
between the following covariates and effect size using 
random- effects meta- regression:
 ► Sex,
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 ► Average age,
 ► Method(s) used to measure visual function (visual 
acuity, visual field),
 ► Duration of follow- up,
 ► Global super- region as defined in the Global Burden 
of Disease study.15
The meta- regression outcome variable will be the log of 
the effect estimate for each study, and the aforementioned 
covariates will be included where data are available to do so.
Sensitivity analyses
We will conduct a sensitivity analysis in which studies are 
excluded if they are judged to be at high risk of bias.
Patient and public involvement statement
As we plan to review existing published literature only, 
this review will be performed without specific patient or 
public involvement.
EthICS And dISSEMInAtIon
Ethics approval is not required, as our review will only 
include published data. Findings will be published in an 
open- access peer- reviewed journal and a summary of results 
will also be included in the ongoing Lancet Global Health 
Commission on Global Eye Health.16 We anticipate that the 
findings will be of considerable interest to those involved in 
eye health provision, as well as the general medical, public 
health, development and governmental sectors.
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